Janney Montgomery Scott LLC Buys 388 Shares of Humana Inc. (NYSE:HUM)

Janney Montgomery Scott LLC boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 11.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,721 shares of the insurance provider’s stock after acquiring an additional 388 shares during the period. Janney Montgomery Scott LLC’s holdings in Humana were worth $1,179,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HUM. Pzena Investment Management LLC lifted its holdings in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after acquiring an additional 1,955,375 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after acquiring an additional 1,050,459 shares in the last quarter. Marshall Wace LLP lifted its holdings in Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after acquiring an additional 774,085 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Humana by 261,025.1% during the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after acquiring an additional 738,701 shares in the last quarter. Finally, Steadfast Capital Management LP bought a new position in Humana during the first quarter worth about $158,813,000. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Down 2.6 %

Shares of NYSE:HUM opened at $275.67 on Friday. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18. The stock has a market cap of $33.19 billion, a PE ratio of 24.47, a P/E/G ratio of 2.29 and a beta of 0.52. The business has a 50 day moving average of $283.00 and a 200-day moving average of $331.80. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities research analysts forecast that Humana Inc. will post 15.83 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.28%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and dropped their price target for the company from $519.00 to $253.00 in a research note on Monday, October 7th. KeyCorp initiated coverage on Humana in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Piper Sandler downgraded Humana from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $392.00 to $274.00 in a research report on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.